Mild Psoriatic Arthritis After csDMARD Failure — Oligoarticular or Entheseal Disease When bDMARD and JAK Inhibitors Are Not Appropriate

This protocol covers patients with mild psoriatic arthritis — oligoarticular or entheseal disease without poor prognostic factors and with limited skin involvement — whose disease did not respond adequately to a conventional synthetic DMARD (csDMARD) and in whom a biologic DMARD or JAK inhibitor is not an appropriate option.

Previous Treatment Line — Goals Not Reached

Inadequate response to csDMARD therapy

The prior treatment step used a csDMARD — methotrexate, leflunomide, or sulfasalazine — with the goal of achieving at least a 50% reduction in disease activity within 3 months and reaching remission or low disease activity by 6 months. When those targets are not met, this protocol defines the evidence-based next step.

Next-Line Treatment Approach

A distinct oral therapeutic class

For patients in this specific situation, guidance supports consideration of an oral agent from a class distinct from csDMARDs — a PDE4 inhibitor. The complete regimen, selection criteria, and monitoring approach are available in the full structured protocol.

Treatment Targets

Measurable improvement is expected by 3 months, with the primary goal of remission or low disease activity reached by 6 months.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2024-225531

In patients with mild disease and an inadequate response to at least one csDMARD, in whom neither a bDMARD nor a JAKi is appropriate, a PDE4 inhibitor may be considered.

'Mild disease' is defined as oligoarticular or entheseal disease without poor prognostic factors and limited skin involvement.

The FOREMOST trial recently confirmed the efficacy of apremilast compared with placebo in oligoarticular PsA.

Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.

View source ↗